Pressor and subpressor doses of angiotensin II increase insulin sensitivity in NIDDM. Dissociation of metabolic and blood pressure effects

What Was Tested

Researchers studied Angiotensin II in the context of low blood pressure and orthostatic hypotension in this randomized controlled trial publication.

BP and heart rate were recorded, and blood samples were collected for serum insulin, C-peptide, potassium, catecholamines, plasma renin activity, and plasma ANG II concentrations.

Who Took Part

According to the abstract, 11 patients were involved.

PubMed indexes the participants as adults, middle-aged adults and older adults, both men and women.

How the Study Was Run

The design is described as randomized, double-blind, placebo-controlled, crossover and parallel-group.

The patients were allocated by chance, so the Angiotensin II group and the comparison group should start out alike.

Blinding on both sides kept the patients and researchers unaware of who received Angiotensin II.

The comparison arm used a placebo, so changes seen with Angiotensin II could be set against what happens without it.

In the crossover set-up each of the patients took both Angiotensin II and the comparison in turn, acting as their own control.

What Was Measured

PubMed files the paper under topics including Aldosterone, Angiotensin II, Blood Pressure, C-Peptide, Cardiac Output, Diabetes Mellitus, Type 2 and Heart Rate.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Angiotensin II in 11 patients in people with low blood pressure and orthostatic hypotension.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

The publication is from 1994 (Diabetes), a journal based in United States.

More context: the Angiotensin II compound page, Low blood pressure and orthostatic hypotension research.